Add Row
Add Element
cropper
update
Lush Skin Insider
update
Add Element
  • Home
  • Categories
    • Experts Talks
    • Myth Busters
    • Research Insights
    • Routine Guides
    • Product Picks
Add Row
Add Element
June 30.2025
3 Minutes Read

FDA Reviews SKINVIVE for Neck Treatment: Updates from June 2025 in Dermatology

Daily Dermatology Times banner with June 30, 2025 date.

The Evolving Landscape of Dermatology: June Highlights

As we step into July 2025, it’s essential to reflect on the significant developments in dermatology from June. This month witnessed remarkable advancements, particularly focused on FDA reviews and clinical findings that could reshape cosmetic treatments and practical applications in skincare.

FDA's Potential Green Light for SKINVIVE by Juvéderm

One of the most talked-about news stories involves the FDA's review of Allergan Aesthetics' supplemental premarket approval (sPMA) for SKINVIVE by Juvéderm. This innovative product aims to target neck lines, a concern that resonates with many adults, particularly women aged 25-45 who are increasingly aware of their skin appearance.

Neck lines, often overlooked in routine skincare, can now potentially be treated with a product designed to enhance the quality and firmness of the skin in this delicate area. If approved, it could offer a new avenue for those looking to maintain their youthful appearance and build confidence.

Top Regulatory Trends Impacting Dermatology

June was also a month rife with important regulatory updates. Industry experts sifted through numerous studies and developments, identifying the crucial topics at the forefront of dermatologic concerns. Highlights from the top five articles of the month included insights into effective treatment options for chronic conditions such as eczema and psoriasis.

This culmination of information equips dermatologists and patients alike with a better understanding of available therapies. For instance, advancements in precision medicine and biologics were front and center, presenting new hope for patients with challenging dermatological diseases. This approach offers tailored treatments that align with patients' unique genetic compositions, fostering improved outcomes.

Why Staying Informed Matters

For individuals interested in skincare and dermatological consultations, understanding these evolving trends is vital. Engaging with trusted sources like Dermatology Times ensures you stay ahead of myths and misbeliefs commonly surrounding skincare products and procedures.

As the month unfolded, a common thread of patient-centered care emerged, emphasizing the necessity for dermatologists to maintain an ongoing dialogue regarding innovations. For consumers, being proactive about accessing reliable information can aid in making informed decisions.

Insights from Experts: What the Future Holds

Industry experts anticipate that the approval of products like SKINVIVE may lead to a wider acceptance of cosmetic treatments aimed not just at the face but the entire body, especially as social influencers share their own experiences. This democratization of dermatological care could help mitigate stigma around procedures that once seemed taboo.

Furthermore, these innovations pave the way for potential shifts in public perception regarding the age-related changes women often face. Empowered by evidence-based insights, women can better advocate for their skincare needs without fear of judgment.

Emphasizing the Importance of Clinical Expertise

As we dive deeper into the world of skincare, it’s essential to acknowledge the clinical expertise a dermatology professional brings to the table. Patients are encouraged to seek consultations with certified dermatologists who can provide personalized assessments and recommendations tailored to individual skin types and concerns.

Regular partner communication and knowledge exchange among dermatology professionals play a critical role in crafting evidence-based solutions, which ultimately benefit patients seeking effective skin care.

Looking Ahead: Preparing for the Next Generation of Skincare

In conclusion, as we look ahead at what July 2025 may bring, it’s crucial to continue tracking breakthroughs in dermatological science and regulatory news. This continuous flow of information equips audiences with insights necessary to navigate the evolving landscape of skincare effectively. Stay informed, challenge misconceptions, and embrace a proactive approach to personal skincare routines.

Engage with Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips to fuel your skincare journey!

Research Insights

Write A Comment

*
*
Related Posts All Posts
07.03.2025

Delgocitinib Emerges as a New Hope for Facial Atopic Dermatitis Treatment

Update Understanding Atopic Dermatitis: Challenges and Innovations The pursuit of effective treatments for atopic dermatitis, especially on sensitive areas like the face and neck, has long been hindered by the delicate nature of the skin in these regions. Patients often face daily struggles with visibility and adherence to conventional treatments. The traditional use of topical corticosteroids comes with its own set of complications, including skin thinning and irritation, heightening the need for innovative solutions. Introducing Delgocitinib: A Game-Changer? Enter delgocitinib ointment, a topical Janus kinase (JAK) inhibitor that's making waves in skincare circles. Approved in Japan in 2020, delgocitinib holds the potential to change how we approach treatment options. Unlike corticosteroids, which can cause long-term skin damage, delgocitinib works by inhibiting inflammatory pathways, possibly reducing the adverse effects associated with traditional therapies. Recent Study Insights: Positive Results from Japan A recent multicenter study from Japan adds to the growing interest in this promising treatment. Involving 40 patients who switched from traditional therapies to delgocitinib, the study reported significant improvements in treatment satisfaction and disease severity after 12 weeks. This study not only highlights delgocitinib's efficacy but also its comfort level compared to steroids and tacrolimus, providing a beacon of hope for those who have struggled with AD. The Broader Impact of Delgocitinib in Dermatology The design and efficacy of delgocitinib present a potential shift in dermatology towards more patient-friendly therapies. Given the visibility of facial and neck lesions, delgocitinib's diminished risk of skin thinning and irritation could enhance both adherence to treatment and overall quality of life for individuals dealing with atopic dermatitis. Future Directions: Where Do We Go from Here? Despite the positive findings, the need for further research is clear. Future studies must evaluate delgocitinib's efficacy across diverse populations and explore its role in combination therapies. As the landscape of skincare continues to evolve, delgocitinib could become a key player in managing skin conditions effectively. FAQs: Your Questions Answered What is delgocitinib? Delgocitinib is a topical JAK inhibitor used to treat atopic dermatitis, particularly in sensitive skin areas. How does it compare to traditional treatments? Delgocitinib may offer fewer adverse effects than traditional topical corticosteroids and calcineurin inhibitors. Is it safe for long-term use? While the initial studies are promising, more research is needed to confirm long-term safety and efficacy. Why This Matters: The Broader Implications for Skincare For adults aged 25-45 who prioritize effective skincare, knowing about options like delgocitinib could lead to informed choices—especially when conventional treatments fall short. This new data strengthens the pool of available evidence-based alternatives, empowering patients to seek out better solutions for their skin health. As the dermatology field advances, embracing innovations like delgocitinib suggests a brighter path for those facing chronic skin conditions. Staying informed and understanding cutting-edge treatments will enable individuals to leverage the best available options for their unique needs.

07.02.2025

Lebrikizumab: A Breakthrough in Atopic Dermatitis for Patients with Skin of Color

Update The Importance of Lebrikizumab in Treating Skin of Color At the forefront of dermatological innovation, lebrikizumab emerges as a transformative therapy for patients with atopic dermatitis (AD), particularly those with pigmented skin who have often been neglected in clinical research. As highlighted by Dr. Anabela Cardoso during the 2025 Revolutionizing Atopic Dermatitis (RAD) conference, the data derived from the phase 3b ADmirable trial set the stage for a new era in patient-centered care specifically tailored for this demographic. What's New About the ADmirable Trial? The ADmirable trial (NCT05372419) represents a significant step forward, being the first study dedicated to evaluating the safety and efficacy of lebrikizumab specifically in adult and adolescent patients with pigmented skin suffering from moderate to severe AD. Historically, clinical trials for dermatological treatments have not sufficiently included diverse populations, leading to less effective therapeutic options for these patients. The findings from the ADmirable trial not only showcase lebrikizumab's potential in alleviating symptoms such as itch and pigmentation problems but also emphasize the urgent need for inclusive research that accurately reflects the patient population. Understanding the Mechanism Behind Lebrikizumab Lebrikizumab operates by targeting interleukin-13 (IL-13), a central cytokine believed to play a pivotal role in the pathophysiology of atopic dermatitis. Dr. Cardoso notes that this mechanism makes lebrikizumab a compelling option when considering treatment plans for patients who have not responded to standard therapies. For clinicians, the clinical implications are clear: the ability to impact the severity of skin issues effectively could translate to greater patient satisfaction and improved quality of life. Patient-Centered Considerations Apart from its clinical efficacy, the administration of lebrikizumab also resonates with patient-centered care philosophies. Factors such as safety, convenience, and the overall experience of receiving injections are crucial for patient adherence to treatment. As patients increasingly seek therapies that not only work but also fit seamlessly into their lifestyles, lebrikizumab checks these boxes, promising a more user-friendly approach to managing AD. The Role of Data Sharing in Advancing Dermatology The RAD conference provided an invaluable platform for professionals in the dermatology field to share insights and data, highlighting how collaborative efforts can lead to advancements in treatment strategies. As Dr. Cardoso pointed out, data-sharing forums are instrumental in fostering innovative ideas and highlighting findings that might otherwise remain obscure. For both clinicians and patients, staying engaged in these discussions can lead to more informed decisions regarding treatment pathways. Future Trends in Atopic Dermatitis Management As innovations like lebrikizumab come to the forefront, we can anticipate a shift in treatment paradigms surrounding atopic dermatitis, especially for patients with skin of color. It not only reshapes how we approach therapy but also underscores the necessity for a diverse representation in clinical trials moving forward. The awareness and implementation of such therapies signify a promising future where personalized medicine truly addresses the needs of all patients. Decisions You Can Make With This Information For patients and caregivers, being equipped with knowledge about the benefits and efficacy of lebrikizumab can empower them to advocate for themselves during medical consultations. Asking healthcare providers about newer treatments, sharing relevant information, and emphasizing the need for therapies that are inclusive can help ensure that more individuals receive effective care tailored specifically for their needs. As more evidence emerges from ongoing studies and patient experiences with lebrikizumab, the dermatology community and patients alike are encouraged to explore this option thoroughly. The shift toward inclusive and effective treatments promises to bring a new level of relief to many who suffer silently, waiting for a solution that truly addresses their unique skin concerns. To gain more insights on how lebrikizumab could revolutionize your treatment or that of someone you care about, consider engaging with clinical professionals or attending future dermatology conferences that keep you abreast of the latest findings in dermatological care.

06.30.2025

Unlock Exclusive Insights from SDPA Summer Dermatology Conference 2025

Update Discovering Advanced Treatments in Dermatology The SDPA Summer Dermatology Conference 2025 has unveiled promising advancements in treatment options for various skin conditions, from rosacea to skin cancer. With a focus on emerging data and expert insights, this conference has become an essential gathering for dermatology professionals looking to enhance their practices. Strong Efficacy of DFD-29 in Treating Rosacea One of the standout highlights from the conference was the promising results of DFD-29, which demonstrated strong efficacy in treating rosacea across different body weights. In phase 3 trials, this innovative therapy outperformed both placebo and traditional treatments like doxycycline. Such findings signal a significant step forward in personalized dermatological care, offering hope for those affected by this chronic condition. The Importance of Early Detection for Skin Cancer Furthermore, the conference emphasized the urgency of early detection and genetic testing in managing aggressive cutaneous squamous cell carcinoma. Even young patients without traditional risk factors are increasingly vulnerable, underscoring the need for heightened awareness and proactive screening methods among healthcare providers. The Rise of JAK Inhibitors JAK inhibitors have also gained traction in dermatology, with new data revealing their effectiveness in conditions like prurigo nodularis and adolescent alopecia areata. Their relevance is increasingly apparent as these targeted therapies continue to reshape treatment protocols, highlighting a trend towards more individualized medicinal approaches in dermatological care. Enhancing Alopecia Diagnosis with Trichoscopy Another notable advancement is the use of trichoscopy, a non-invasive technique that enhances the diagnosis of alopecia. This method improves diagnostic speed and accuracy while reducing the need for biopsies—a welcome change for patients who are often anxious about invasive procedures. Maintaining Repigmentation in Vitiligo For patients dealing with vitiligo, ongoing therapy is essential not only for initiating repigmentation but also for maintaining it over time. The conference underscored the necessity of continued treatment to prevent relapse and sustain the benefits achieved, an insight that is crucial for effective long-term management. Future Predictions: The Evolving Landscape of Dermatological Treatments As we look to the future, the insights gleaned from this conference reflect a rapidly evolving landscape in dermatology. With ongoing research and development in treatments, skin health management is likely to become even more personalized and effective, meeting the unique needs of patients worldwide. Final Thoughts The SDPA 2025 Summer Dermatology Conference provided invaluable insights into the latest advancements in skincare and treatment modalities, emphasizing the critical nature of innovation in this ever-evolving field. For professionals and patients alike, staying informed about these developments is paramount to achieving optimal outcomes. To keep abreast of further advancements in dermatology and to access exclusive insights from this significant event, consider subscribing to receive the latest updates directly.

Add Row
Add Element
cropper
update
MYBRANDINGLOGO
cropper
update

  • update
  • update
  • update
  • update
  • update
  • update
  • update
Add Element

ABOUT US

Our goal is to become a trusted voice in the cluttered skincare industry, following the “Science over trends” and bridging the gap between cosmetic dermatology and evidence-based skincare.

We offer dermatologist-backed advice, simplifying complex medical research into actionable tips. This focus directly combats misinformation and meets the demand for credible skincare guidance.
 
Our team of experienced reporters is committed to bring you expert-backed articles, dermatologists' insights, and myth-busting content that targets misinformation, delivered to you in easy-to-digest format like infographics, explainer videos, podcasts, interviews, breaking down medical research into actionable tips for skin health.

{"company":"Lush Skin Insider","address":"-","city":"Vernon Hills","state":"IL","zip":"60061","email":"mh.mailq@gmail.com","tos":"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","privacy":"PHA+PHN0cm9uZz5QUklWQUNZPC9zdHJvbmc+PC9wPgoKPHA+PHN0cm9uZz5UaGUgaW5mb3JtYXRpb24gcHJvdmlkZWQgZHVyaW5nIHRoaXMgcmVnaXN0cmF0aW9uIGlzIGtlcHQgcHJpdmF0ZSBhbmQgY29uZmlkZW50aWFsLCBhbmQgd2lsbCBuZXZlciBiZSBkaXN0cmlidXRlZCwgY29waWVkLCBzb2xkLCB0cmFkZWQgb3IgcG9zdGVkIGluIGFueSB3YXksIHNoYXBlIG9yIGZvcm0uIFRoaXMgaXMgb3VyIGd1YXJhbnRlZS48L3N0cm9uZz48L3A+Cgo8cD48c3Ryb25nPklOREVNTklUWTwvc3Ryb25nPjwvcD4KCjxwPjxlbT5Zb3UgYWdyZWUgdG8gaW5kZW1uaWZ5IGFuZCBob2xkIHVzLCBhbmQgaXRzIHN1YnNpZGlhcmllcywgYWZmaWxpYXRlcywgb2ZmaWNlcnMsIGFnZW50cywgY28tYnJhbmRlcnMgb3Igb3RoZXIgcGFydG5lcnMsIGFuZCBlbXBsb3llZXMsIGhhcm1sZXNzIGZyb20gYW55IGNsYWltIG9yIGRlbWFuZCwgaW5jbHVkaW5nIHJlYXNvbmFibGUgYXR0b3JuZXlzJiMzOTsgZmVlcywgbWFkZSBieSBhbnkgdGhpcmQgcGFydHkgZHVlIHRvIG9yIGFyaXNpbmcgb3V0IG9mIENvbnRlbnQgeW91IHJlY2VpdmUsIHN1Ym1pdCwgcmVwbHksIHBvc3QsIHRyYW5zbWl0IG9yIG1ha2UgYXZhaWxhYmxlIHRocm91Z2ggdGhlIFNlcnZpY2UsIHlvdXIgdXNlIG9mIHRoZSBTZXJ2aWNlLCB5b3VyIGNvbm5lY3Rpb24gdG8gdGhlIFNlcnZpY2UsIHlvdXIgdmlvbGF0aW9uIG9mIHRoZSBUT1MsIG9yIHlvdXIgdmlvbGF0aW9uIG9mIGFueSByaWdodHMgb2YgYW5vdGhlci48L2VtPjwvcD4KCjxwPjxzdHJvbmc+RElTQ0xBSU1FUiBPRiBXQVJSQU5USUVTPC9zdHJvbmc+PC9wPgoKPHA+PHN0cm9uZz5ZT1UgRVhQUkVTU0xZIFVOREVSU1RBTkQgQU5EIEFHUkVFIFRIQVQ6PC9zdHJvbmc+PC9wPgoKPG9sPgoJPGxpPllPVVIgVVNFIE9GIFRIRSBTRVJWSUNFIElTIEFUIFlPVVIgU09MRSBSSVNLLiBUSEUgU0VSVklDRSBJUyBQUk9WSURFRCBPTiBBTiAmcXVvdDtBUyBJUyZxdW90OyBBTkQgJnF1b3Q7QVMgQVZBSUxBQkxFJnF1b3Q7IEJBU0lTLiAsLiBBTkQgVVMsIElUJiMzOTtTIENVU1RPTUVSUywgRVhQUkVTU0xZIERJU0NMQUlNUyBBTEwgV0FSUkFOVElFUyBPRiBBTlkgS0lORCwgV0hFVEhFUiBFWFBSRVNTIE9SIElNUExJRUQsIElOQ0xVRElORywgQlVUIE5PVCBMSU1JVEVEIFRPIFRIRSBJTVBMSUVEIFdBUlJBTlRJRVMgT0YgTUVSQ0hBTlRBQklMSVRZLCBGSVRORVNTIEZPUiBBIFBBUlRJQ1VMQVIgUFVSUE9TRSBBTkQgTk9OLUlORlJJTkdFTUVOVC48L2xpPgoJPGxpPk1BS0VTIE5PIFdBUlJBTlRZIFRIQVQgKGkpIFRIRSBTRVJWSUNFIFdJTEwgTUVFVCBZT1VSIFJFUVVJUkVNRU5UUywgKGlpKSBUSEUgU0VSVklDRSBXSUxMIEJFIFVOSU5URVJSVVBURUQsIFRJTUVMWSwgU0VDVVJFLCBPUiBFUlJPUi1GUkVFLCAoaWlpKSBUSEUgUkVTVUxUUyBUSEFUIE1BWSBCRSBPQlRBSU5FRCBGUk9NIFRIRSBVU0UgT0YgVEhFIFNFUlZJQ0UgV0lMTCBCRSBBQ0NVUkFURSBPUiBSRUxJQUJMRSwgQU5EIChpdikgQU5ZIEVSUk9SUyBJTiBUSEUgU09GVFdBUkUgV0lMTCBCRSBDT1JSRUNURUQuPC9saT4KCTxsaT5BTlkgTUFURVJJQUwgRE9XTkxPQURFRCBPUiBPVEhFUldJU0UgT0JUQUlORUQgVEhST1VHSCBUSEUgVVNFIE9GIFRIRSBTRVJWSUNFIElTIERPTkUgQVQgWU9VUiBPV04gRElTQ1JFVElPTiBBTkQgUklTSyBBTkQgVEhBVCBZT1UgV0lMTCBCRSBTT0xFTFkgUkVTUE9OU0lCTEUgRk9SIEFOWSBEQU1BR0UgVE8gWU9VUiBDT01QVVRFUiBTWVNURU0gT1IgTE9TUyBPRiBEQVRBIFRIQVQgUkVTVUxUUyBGUk9NIFRIRSBET1dOTE9BRCBPRiBBTlkgU1VDSCBNQVRFUklBTC48L2xpPgoJPGxpPk5PIEFEVklDRSBPUiBJTkZPUk1BVElPTiwgV0hFVEhFUiBPUkFMIE9SIFdSSVRURU4sIE9CVEFJTkVEIEJZIFlPVSBGUk9NIE9SIFRIUk9VR0ggT1IgRlJPTSBUSEUgU0VSVklDRSBTSEFMTCBDUkVBVEUgQU5ZIFdBUlJBTlRZIE5PVCBFWFBSRVNTTFkgU1RBVEVEIElOIFRIRSBUT1MuPC9saT4KPC9vbD4KCjxwPjxzdHJvbmc+TElNSVRBVElPTiBPRiBMSUFCSUxJVFk8L3N0cm9uZz48L3A+Cgo8cD5ZT1UgRVhQUkVTU0xZIFVOREVSU1RBTkQgQU5EIEFHUkVFIFRIQVQgQU5EIFNIQUxMIE5PVCBCRSBMSUFCTEUgRk9SIEFOWSBESVJFQ1QsIElORElSRUNULCBJTkNJREVOVEFMLCBTUEVDSUFMLCBDT05TRVFVRU5USUFMIE9SIEVYRU1QTEFSWSBEQU1BR0VTLCBJTkNMVURJTkcgQlVUIE5PVCBMSU1JVEVEIFRPLCBEQU1BR0VTIEZPUiBMT1NTIE9GIFBST0ZJVFMsIEdPT0RXSUxMLCBVU0UsIERBVEEgT1IgT1RIRVIgSU5UQU5HSUJMRSBMT1NTRVMgKEVWRU4gSUYgSEFTIEJFRU4gQURWSVNFRCBPRiBUSEUgUE9TU0lCSUxJVFkgT0YgU1VDSCBEQU1BR0VTKSwgUkVTVUxUSU5HIEZST006PC9wPgoKPG9sPgoJPGxpPlRIRSBVU0UgT1IgVEhFIElOQUJJTElUWSBUTyBVU0UgVEhFIFNFUlZJQ0U7PC9saT4KCTxsaT5USEUgQ09TVCBPRiBQUk9DVVJFTUVOVCBPRiBTVUJTVElUVVRFIEdPT0RTIEFORCBTRVJWSUNFUyBSRVNVTFRJTkcgRlJPTSBBTlkgR09PRFMsIERBVEEsIElORk9STUFUSU9OIE9SIFNFUlZJQ0VTIFBVUkNIQVNFRCBPUiBPQlRBSU5FRCBPUiBNRVNTQUdFUyBSRUNFSVZFRCBPUiBUUkFOU0FDVElPTlMgRU5URVJFRCBJTlRPIFRIUk9VR0ggT1IgRlJPTSBUSEUgU0VSVklDRTs8L2xpPgoJPGxpPlVOQVVUSE9SSVpFRCBBQ0NFU1MgVE8gT1IgQUxURVJBVElPTiBPRiBZT1VSIFRSQU5TTUlTU0lPTlMgT1IgREFUQTs8L2xpPgoJPGxpPlNUQVRFTUVOVFMgT1IgQ09ORFVDVCBPRiBBTlkgVEhJUkQgUEFSVFkgT04gVEhFIFNFUlZJQ0U7IE9SPC9saT4KCTxsaT5BTlkgT1RIRVIgTUFUVEVSIFJFTEFUSU5HIFRPIFRIRSBTRVJWSUNFLjwvbGk+Cjwvb2w+Cgo8cD48dT5CeSByZWdpc3RlcmluZyBhbmQgc3Vic2NyaWJpbmcgdG8gb3VyIGVtYWlsIGFuZCBTTVMgc2VydmljZSwgYnkgb3B0LWluLCBvbmxpbmUgcmVnaXN0cmF0aW9uIG9yIGJ5IGZpbGxpbmcgb3V0IGEgY2FyZCwgJnF1b3Q7eW91IGFncmVlIHRvIHRoZXNlIFRFUk1TIE9GIFNFUlZJQ0UmcXVvdDsgYW5kIHlvdSBhY2tub3dsZWRnZSBhbmQgdW5kZXJzdGFuZCB0aGUgYWJvdmUgdGVybXMgb2Ygc2VydmljZSBvdXRsaW5lZCBhbmQgZGV0YWlsZWQgZm9yIHlvdSB0b2RheS48L3U+PC9wPgoKPHA+Jm5ic3A7PC9wPgo8aGlnaGxpZ2h0IGNsYXNzPSJjb21wYW55TmFtZVVwZGF0ZSI+THVzaCBTa2luIEluc2lkZXI8L2hpZ2hsaWdodD48YnIgLz4KPGhpZ2hsaWdodCBjbGFzcz0iY29tcGFueUFkZHJlc3NVcGRhdGUiPi0sIFZlcm5vbiBIaWxscywgSUwgNjAwNjE8L2hpZ2hsaWdodD48YnIgLz4KPGhpZ2hsaWdodCBjbGFzcz0iY29tcGFueVBob25lVXBkYXRlIj44NDc3NjA1MDAwPC9oaWdobGlnaHQ+PGJyIC8+CjxoaWdobGlnaHQgY2xhc3M9ImNvbXBhbnlFbWFpbFVwZGF0ZSI+bWgubWFpbHFAZ21haWwuY29tPC9oaWdobGlnaHQ+"}
Add Row
Add Element

© 2025 Lush Skin Insider All Rights Reserved. -, Vernon Hills, IL 60061 . Contact Us . Terms of Service . Privacy Policy

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*